Weaponised Capacity
The CDMO Report - Q1 2026
The definitive guide to CDMO strategy, selection, and valuation in the post-BIOSECURE era. Why capacity no longer wins and where value is migrating in contract manufacturing.
What This Report Covers
The collision of geopolitical decoupling, legislated margin compression, and explosive modality complexity has permanently ended the transactional CDMO model. This report maps how each force reshapes the sector across geography, modality, margin structure, capacity access, pricing architecture, technology, valuation, and strategic action.
Structured around a single diagnostic binary: Generalist versus Scaled Specialist. Answers three questions for three audiences. For CDMO operators: which assets to shed and where to deploy capex. For biopharma procurement: how to structure contracts and calculate true total cost of ownership. For PE sponsors and corporate development: what multiples to underwrite and which modality exposures justify premium pricing.
Key Topics
The Three-Force Collision
BIOSECURE Act, IRA margin compression, and modality complexity. Why they are multiplicative, not additive, and why every traditional escape route is closed.
Generalist vs Scaled Specialist
The diagnostic binary defining CDMO valuations. Why premium multiples belong exclusively to operators owning defensible bottleneck positions.
Ghost Capacity
Why announced capacity does not equal commercially schedulable output. The gap between press releases and validated production lines.
BIOSECURE Act Implications
How the legislation fractures global pharmaceutical supply chains. WuXi valuation signatures, vendor transition timelines, and the 2026-2027 decision deadline.
GLP-1 Demand Displacement
How the $50B+ GLP-1 market consumed sterile fill-finish capacity so aggressively it displaced all non-GLP-1 injectable programmes.
ADC Manufacturing Complexity
400+ ADC assets requiring OEB 4-5 containment. Three-supply-chain synchronisation under a single quality system.
PE Exit Pressure & Consolidation
Platform fatigue across PE-backed CDMOs. Which operators compound value and which quietly fail this cycle.
Talent as Binding Constraint
Where the qualified people are and where they are not. Human capital as the true limiter on capacity utilisation.